Azo-based hypoxic-activated 6-diazo-5-oxo-L-norleucine (DON) prodrug combined with vascular disrupting agent nanoparticles for tumor-selective glutamine metabolism blockade
Hang Xu, Mengfei Zheng, Chenguang Yang, Kun Wang, Zheng Lv, Zhilin Liu, Zhaohui Tang, Xuesi Chen
Topics & Concepts
ProdrugGlutamineChemistryIn vivoPharmacologyCancer cellMetabolismNorleucineTumor hypoxiaBiochemistryCancer researchCancerBiologyMedicineInternal medicineLeucineAmino acidRadiation therapyBiotechnologyCancer, Hypoxia, and MetabolismBiochemical and Molecular ResearchCancer Research and Treatments